Skip to main content
NASDAQ:STRO

Sutro Biopharma News Headlines

$20.23
+0.44 (+2.22 %)
(As of 05/18/2021 04:30 PM ET)
Add
Compare
Today's Range
$19.39
$20.37
50-Day Range
$18.52
$23.82
52-Week Range
$7.06
$28.30
Volume662,705 shs
Average Volume507,750 shs
Market Capitalization$932.87 million
P/E RatioN/A
Dividend YieldN/A
Beta0.8

Headlines

Sutro Biopharma (NASDAQ STRO) News Headlines Today

SourceHeadline
$10.15 Million in Sales Expected for Sutro Biopharma, Inc. (NASDAQ:STRO) This Quarter$10.15 Million in Sales Expected for Sutro Biopharma, Inc. (NASDAQ:STRO) This Quarter
americanbankingnews.com - May 18 at 1:36 AM
 Brokerages Expect Sutro Biopharma, Inc. (NASDAQ:STRO) Will Announce Earnings of -$0.47 Per Share Brokerages Expect Sutro Biopharma, Inc. (NASDAQ:STRO) Will Announce Earnings of -$0.47 Per Share
americanbankingnews.com - May 16 at 6:10 PM
Sutro Biopharma, Inc. Forecasted to Post Q1 2022 Earnings of ($0.54) Per Share (NASDAQ:STRO)Sutro Biopharma, Inc. Forecasted to Post Q1 2022 Earnings of ($0.54) Per Share (NASDAQ:STRO)
americanbankingnews.com - May 15 at 4:18 AM
New Forecasts: Heres What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
nasdaq.com - May 14 at 4:58 PM
Sutro Biopharma to Participate in Upcoming Virtual Investor ConferencesSutro Biopharma to Participate in Upcoming Virtual Investor Conferences
finance.yahoo.com - May 14 at 11:58 AM
Sutro Biopharma, Inc. Expected to Earn Q4 2022 Earnings of ($0.64) Per Share (NASDAQ:STRO)Sutro Biopharma, Inc. Expected to Earn Q4 2022 Earnings of ($0.64) Per Share (NASDAQ:STRO)
americanbankingnews.com - May 14 at 10:34 AM
Q2 2021 EPS Estimates for Sutro Biopharma, Inc. Lifted by Truist Securiti (NASDAQ:STRO)Q2 2021 EPS Estimates for Sutro Biopharma, Inc. Lifted by Truist Securiti (NASDAQ:STRO)
americanbankingnews.com - May 14 at 8:38 AM
Sutro Biopharma (NASDAQ:STRO) Trading Down 4.7%Sutro Biopharma (NASDAQ:STRO) Trading Down 4.7%
americanbankingnews.com - May 13 at 12:46 PM
FY2025 EPS Estimates for Sutro Biopharma, Inc. (NASDAQ:STRO) Cut by AnalystFY2025 EPS Estimates for Sutro Biopharma, Inc. (NASDAQ:STRO) Cut by Analyst
americanbankingnews.com - May 13 at 11:30 AM
Sutro Biopharma, Inc. (NASDAQ:STRO) to Post Q1 2022 Earnings of ($0.54) Per Share, Wedbush ForecastsSutro Biopharma, Inc. (NASDAQ:STRO) to Post Q1 2022 Earnings of ($0.54) Per Share, Wedbush Forecasts
americanbankingnews.com - May 13 at 10:38 AM
News Flash: Analysts Just Made A Substantial Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) ForecastsNews Flash: Analysts Just Made A Substantial Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts
finance.yahoo.com - May 13 at 8:19 AM
FY2021 Earnings Estimate for Sutro Biopharma, Inc. Issued By Wedbush (NASDAQ:STRO)FY2021 Earnings Estimate for Sutro Biopharma, Inc. Issued By Wedbush (NASDAQ:STRO)
americanbankingnews.com - May 12 at 7:26 AM
The Sutro Biopharma (NASDAQ:STRO) Share Price Has Gained 96% And Shareholders Are Hoping For MoreThe Sutro Biopharma (NASDAQ:STRO) Share Price Has Gained 96% And Shareholders Are Hoping For More
nasdaq.com - May 11 at 8:56 PM
Reviewing Sutro Biopharma (NASDAQ:STRO) and Gene Biotherapeutics (OTCMKTS:CRXM)Reviewing Sutro Biopharma (NASDAQ:STRO) and Gene Biotherapeutics (OTCMKTS:CRXM)
americanbankingnews.com - May 11 at 3:18 PM
Sutro Biopharma, Inc. (NASDAQ:STRO) to Post Q2 2021 Earnings of ($0.50) Per Share, Wedbush ForecastsSutro Biopharma, Inc. (NASDAQ:STRO) to Post Q2 2021 Earnings of ($0.50) Per Share, Wedbush Forecasts
americanbankingnews.com - May 11 at 7:56 AM
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue EstimatesSutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 7 at 12:48 PM
Five-year-old girl killed in crash during police pursuit identifiedFive-year-old girl killed in crash during police pursuit identified
msn.com - April 30 at 8:35 AM
$6.92 Million in Sales Expected for Sutro Biopharma, Inc. (NASDAQ:STRO) This Quarter$6.92 Million in Sales Expected for Sutro Biopharma, Inc. (NASDAQ:STRO) This Quarter
americanbankingnews.com - April 30 at 1:06 AM
Sutro Biopharma, Inc. (NASDAQ:STRO) Expected to Announce Earnings of -$0.61 Per ShareSutro Biopharma, Inc. (NASDAQ:STRO) Expected to Announce Earnings of -$0.61 Per Share
americanbankingnews.com - April 29 at 12:14 AM
Sutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific OfficerSutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific Officer
finance.yahoo.com - April 28 at 6:26 AM
Sutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific OfficerSutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific Officer
finance.yahoo.com - April 28 at 6:26 AM
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of "Buy" from BrokeragesSutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of "Buy" from Brokerages
americanbankingnews.com - April 28 at 2:26 AM
Oakley Sutro vs Rudy Project Cutline: which is the king of the cycling sunglasses?Oakley Sutro vs Rudy Project Cutline: which is the king of the cycling sunglasses?
msn.com - April 21 at 10:48 AM
Is STRO Stock A Buy or Sell?Is STRO Stock A Buy or Sell?
finance.yahoo.com - April 19 at 8:26 PM
Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with MerckSutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck
finance.yahoo.com - April 15 at 10:16 AM
Have Insiders Been Buying Sutro Biopharma, Inc. (NASDAQ:STRO) Shares?Have Insiders Been Buying Sutro Biopharma, Inc. (NASDAQ:STRO) Shares?
finance.yahoo.com - March 22 at 6:51 PM
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory BoardSutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
finance.yahoo.com - March 22 at 8:49 AM
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Lags Revenue EstimatesSutro Biopharma, Inc. (STRO) Reports Q4 Loss, Lags Revenue Estimates
finance.yahoo.com - March 18 at 10:13 AM
Why Sutro Biopharma (STRO) Might Surprise This Earnings SeasonWhy Sutro Biopharma (STRO) Might Surprise This Earnings Season
finance.yahoo.com - March 12 at 2:26 PM
Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseSutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
finance.yahoo.com - March 8 at 2:08 PM
Sutro Biopharma to Participate in the Cowen 41st Annual Healthcare ConferenceSutro Biopharma to Participate in the Cowen 41st Annual Healthcare Conference
finance.yahoo.com - February 23 at 9:49 AM
Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian CancerSutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer
finance.yahoo.com - January 21 at 7:36 AM
Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare ConferenceSutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
finance.yahoo.com - January 5 at 11:10 AM
Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters Option to Purchase Additional SharesSutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - December 11 at 6:55 PM
Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual MeetingSutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
finance.yahoo.com - December 7 at 5:35 PM
Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common StockSutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock
finance.yahoo.com - December 7 at 5:35 PM
Sutro Bios Ovarian Cancer Treatment Ready for the Next LevelSutro Bio's Ovarian Cancer Treatment Ready for the Next Level
msn.com - December 4 at 6:03 PM
Why Sutro, Lumos And More Health Care Stocks Are Moving TodayWhy Sutro, Lumos And More Health Care Stocks Are Moving Today
finance.yahoo.com - December 3 at 4:49 PM
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian CancerSutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
finance.yahoo.com - December 3 at 4:49 PM
Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of DirectorsSutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors
finance.yahoo.com - December 1 at 1:47 PM
Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian CancerSutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
markets.businessinsider.com - November 24 at 7:41 AM
Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor RelationsSutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
finance.yahoo.com - November 18 at 8:21 AM
Sutro Biopharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next YearSutro Biopharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
finance.yahoo.com - November 9 at 2:15 PM
If You Had Bought Sutro Biopharma (NASDAQ:STRO) Stock A Year Ago, You Could Pocket A 27% Gain TodayIf You Had Bought Sutro Biopharma (NASDAQ:STRO) Stock A Year Ago, You Could Pocket A 27% Gain Today
finance.yahoo.com - November 3 at 6:03 PM
Sutro Biopharma IncSutro Biopharma Inc
bloomberg.com - October 24 at 6:51 PM
Sutro Biopharma Named Best New Drug Developer at the 7th Annual World ADCSutro Biopharma Named Best New Drug Developer at the 7th Annual World ADC
finance.yahoo.com - September 21 at 9:26 AM
Stock Alert: Sutro Biopharma Gains 9%Stock Alert: Sutro Biopharma Gains 9%
nasdaq.com - September 14 at 2:29 PM
Five Prime hands off space to Sutro in big South City sublease dealFive Prime hands off space to Sutro in big South City sublease deal
bizjournals.com - September 10 at 5:26 PM
Sutro Bios lead drug continues to show benefit in early-stage ovarian cancer studySutro Bio's lead drug continues to show benefit in early-stage ovarian cancer study
seekingalpha.com - September 9 at 11:49 PM
Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global MeetingSutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global Meeting
finance.yahoo.com - September 9 at 11:49 PM
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.